Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial

Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial

Abstract Background Familial Mediterranean fever (FMF) is an inherited disorder caused by a number of mutations of the Mediterranean fever (MEFV) gene, coding a protein named pyrin that acts as a major regulatory component of the inflammasome. The first-line drug for FMF treatment is colchicine, but...

Full description

Bibliographic Details
Main Authors: Tomohiro Koga, Shuntaro Sato, Junya Miyamoto, Naoko Hagimori, Yurika Kawazoe, Kumiko Arinaga, Chizu Fukushima, Hiroshi Yamamoto, Atsushi Kawakami
Format: Article
Language:English
Published: BMC 2018-12-01
Series:Trials
Subjects:
IL-6
Placebo
Tocilizumab
FMF
Colchicine-resistant
Online Access:http://link.springer.com/article/10.1186/s13063-018-3105-6

Internet

http://link.springer.com/article/10.1186/s13063-018-3105-6

Similar Items